Vaccentis is proud to see the interview of Prof. Dr. med. Martin Marszalek in KURIER Medienhaus adressing the unmed medical need for the adjuvant treatment of renal cell carcinoma.
Prof. Marszalek is highlighting the need for the development of treatment options, including VCC-001, to reduce side effects and improve quality of life of cancer patients.
